Table 3.
Characteristics of spontaneous reports in the GlaxoSmithKline Vaccines spontaneous report database, by vaccine
| Vaccine | Age at event (years): median (Q1–Q3) | Female (%) | Year of reporting: median (Q1, Q3) | Number (%) of spontaneous reports | Number of countries |
|---|---|---|---|---|---|
| Engerix ™ | 31.0 (18.0, 43.0) | 64.2 | 1999 (1993, 2005) | 34,347 (23.4 %) | 92 |
| Havrix™ | 23.0 (11.0, 40.0) | 57.8 | 2004 (1998, 2007) | 9,066 (6.2 %) | 58 |
| Cervarix™ | 15.0 (12.0, 17.0) | 99.5 | 2009 (2008, 2009) | 3,437 (2.3 %) | 63 |
| Infanrix™ | 5.0 (1.5, 10.0) | 45.5 | 2006 (2003, 2007) | 9,732 (6.6 %) | 59 |
| Infanrix™ Hib | 1.5 (0.8, 1.9) | 42.5 | 2002 (1999, 2003) | 1,027 (0.7 %) | 21 |
| Rotarix™ | 0.3 (0.2, 0.6) | 46.3 | 2008 (2007, 2009) | 2,800 (1.9 %) | 73 |
| Fluarix™ | 41.0 (19.0, 60.0) | 60.0 | 2005 (2002, 2007) | 6,864 (4.7 %) | 69 |
| Twinrix™ | 31.0 (19.0, 45.0) | 57.6 | 2006 (2003, 2008) | 9,836 (6.7 %) | 51 |